Practical considerations and role of Daratumumab retreatment for relapsed refractory Multiple Myeloma

Kim, E. Bridget; Harrington, Cynthia; Yee, Andrew J.; O’Donnell, Elizabeth; Branagan, Andrew R.; Burke, Jack D.; Raje, Noopur

doi:10.1016/j.clml.2019.09.435

Cited by 4 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the next years, more and more patients will eventually be exposed or refractory to anti-CD38 naked mAbs after first relapse, thus questioning the current treatment sequencing in RRMM patients. Initial reports of the suboptimal efficacy of retreatment with anti-CD38 mAbs in a small series of patients are beginning to emerge [93] and will require prospective confirmation in a significant number of patients. This issue may be overcome by using different anti-CD38 mAbs with unique mechanisms of action [94].…”

Section: Future Directions and Conclusionmentioning

confidence: 99%

Monoclonal Antibodies to Treat Multiple Myeloma: A Dream Come True

D’Agostino

Innorcia

Boccadoro

et al. 2020

IJMS

View full text Add to dashboard Cite

Immunotherapy is increasingly used in the treatment of multiple myeloma (MM). Monoclonal antibodies (mAbs) are safe and effective ways to elicit immunotherapeutic responses. In 2015, daratumumab has become the first mAb approved by the Food and Drug Administration for clinical use in MM and, in the last 5 years, a lot of clinical and preclinical research has been done to optimize the use of this drug class. Currently, mAbs have already become part of standard-of-care combinations for the treatment of relapsed/refractory MM and very soon they will also be used in the frontline setting. The success of simple mAbs (‘naked mAbs’) prompted the development of new types of molecules. Antibody–drug conjugates (ADCs) are tumor-targeting mAbs that release a cytotoxic payload into the tumor cells upon antigen binding in order to destroy them. Bispecific antibodies (BiAbs) are mAbs simultaneously targeting a tumor-associated antigen and an immune cell-associated antigen in order to redirect the immune cell cytotoxicity against the tumor cell. These different constructs produced solid preclinical data and promising clinical data in phase I/II trials. The aim of this review article is to summarize all the recent developments in the field, including data on naked mAbs, ADCs and BiAbs.

show abstract

Section: Future Directions and Conclusionmentioning

confidence: 99%

Monoclonal Antibodies to Treat Multiple Myeloma: A Dream Come True

D’Agostino

Innorcia

Boccadoro

et al. 2020

IJMS

View full text Add to dashboard Cite

show abstract

“…Nooka et al recently reported that DPd may produce clinical responses in patients previously exposed to daratumumab [43]. However, in another retrospective study evaluating reinitiation of daratumumab after a break due to disease progression or because of delay in the same therapy in 19 patients with heavily pretreated RRMM, the conclusion of the authors was that ' … response rates with daratumumab retreatment are low' [73].…”

Section: Anti-cd38 Retreatment and Refractorinessmentioning

confidence: 99%

Monoclonal antibodies in relapsed/refractory myeloma: updated evidence from clinical trials, real-life studies, and meta-analyses

Musto

Rocca

2020

Expert Review of Hematology

View full text Add to dashboard Cite

Introduction: In the last few years, monoclonal antibodies have rapidly modified the therapeutic strategies for treating patients with multiple myeloma. Areas covered: In this review, the most recent literature data regarding indications for which monoclonal antibodies are currently or will be shortly approved as salvage therapies in relapsed/refractory myeloma are discussed. In particular, updated results until March 22, 2020 of antibodies directed against CD38 (daratumumab and isatuximab), SLAMF7 (elotuzumab), BCMA (GSK2857916/belantamab mafodotin), and PD-1/PD-1 L axis (nivolumab and pembrolizumab) will be analyzed in detail. Expert opinion: Monoclonal antibodies represent a new, very effective approach that will open novel and dynamic treatment scenarios for myeloma patients in the coming years. Optimal positioning and selection of different antibodies that are or will be soon available, appropriate combinations and careful evaluation of possible new toxicities should be considered in the future management of these patients.

show abstract

Evolving Role of Daratumumab: From Backbencher to Frontline Agent

Jain

Ramasamy

2020

Clinical Lymphoma Myeloma and Leukemia

View full text Add to dashboard Cite

Practical considerations and role of Daratumumab retreatment for relapsed refractory Multiple Myeloma

Cited by 4 publications

References 0 publications

Monoclonal Antibodies to Treat Multiple Myeloma: A Dream Come True

Monoclonal Antibodies to Treat Multiple Myeloma: A Dream Come True

Monoclonal antibodies in relapsed/refractory myeloma: updated evidence from clinical trials, real-life studies, and meta-analyses

Evolving Role of Daratumumab: From Backbencher to Frontline Agent

Contact Info

Product

Resources

About